New data reveals that TREMFYA (guselkumab) demonstrates impressive efficacy in managing Crohn’s disease by achieving up to 94% clinical and endoscopic remission after three years of treatment. This breakthrough highlights TREMFYA as a promising biologic therapy for patients suffering from moderate to severe Crohn’s disease, offering sustained disease control and improved quality of life. The results underscore the importance of long-term maintenance therapy targeting interleukin-23 (IL-23) pathways to reduce inflammation and promote intestinal healing. As traditional treatments sometimes fail to maintain remission, TREMFYA’s novel mechanism provides a valuable option for patients and healthcare providers. These findings are pivotal in advancing Crohn’s disease management strategies. Continued research and real-world data will help further define the role of guselkumab in comprehensive care plans. Overall, TREMFYA’s up to 94% remission rate marks a significant step forward in chronic inflammatory bowel disease treatment.
PluangNew data shows Connecticut student test scores improve in 2025-26 but remain below pre-pandemic levels
October 14, 2026
New data released on August 31, 2026, reveals that Connecticut student test scores have risen during the 2025-26 academic year, signaling progress in student performance